Table 1

Clinical characteristics of the PSS cohort

Age (years)60 (49.8, 67.8)
Sex604 women, 35 men
Anti-Ro/anti-La positivity (n (%) of patients)544 (85.1%)
Symptom duration (years)10 (5–16)
Disease duration (years) AECG diagnosis5 (2–10)
ESSDAI3 (1–7)
Evidence of systemic manifestation*80.4%
IgG (g/l)15.5 (1.6–20.2)
Paraproteinaemia† (n (%) of patients)29 (4.5%)
CRP (mg/l)1.5 (2.5–4.2)
ESR (mm in first h)20 (10–38)
Lymphoma (n (%) of patients)35 (5.3%)
Disease damage (Physician VAS (0–10))3 (2–4)
ESSPRI (0–10)5.7 (3.7–7.0)
Dryness (EULAR sicca score (0–10))6 (4–8)
Physical fatigue (0–7)4 (2.5–5.0)
Mental fatigue (0–7)3 (1.0–4.5)
Overall fatigue (0–100)60 (32–75)
Pain (0–10)5 (2–7)
Anxiety (HADS-A)7 (4–11)
Depression (HADS-D)5 (3–9)
Daytime sleepiness (ESS)8 (4–12)
Orthostatic intolerance (OGS)3 (1–5)
  • Summary table presented as median values and IQRs (25th and 75th percentiles) or sample size and percentages.

  • *Presence of disease activity in any ESSDAI domains except glandular domain alone.

  • †25 patients had paraproteinaemia, 4 other had faint monoclonal bands but no quantifiable paraproteins.

  • AECG, American European Consensus Group; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; ESS, Epworth Sleepiness Scale; ESSDAI, European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index; HADS, Hospital Anxiety and Depression Scale; OGS, Orthostatic grading scale.